119 related articles for article (PubMed ID: 9175716)
21. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
22. DNA-DNA interstrand cross-linking by 2,5-bis(1-aziridinyl)-3,6-bis(carbethoxyamino)-1,4-benzoquinone: covalent structure of the dG-to-dG cross-links in calf thymus DNA and a synthetic DNA duplex.
Alley SC; Hopkins PB
Chem Res Toxicol; 1994; 7(5):666-72. PubMed ID: 7841346
[TBL] [Abstract][Full Text] [Related]
23. DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone.
Sariban E; Kohn KW; Zlotogorski C; Laurent G; D'Incalci M; Day R; Smith BH; Kornblith PL; Erickson LC
Cancer Res; 1987 Aug; 47(15):3988-94. PubMed ID: 3038305
[TBL] [Abstract][Full Text] [Related]
24. The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.
Feun LG; Savaraj N; Lu K; Guo Z; Raulston LG; Benjamin RS; Fields WS; Loo TL
J Neurooncol; 1983; 1(3):219-24. PubMed ID: 6678971
[TBL] [Abstract][Full Text] [Related]
25. Modification of the alkaline Comet assay to allow simultaneous evaluation of mitomycin C-induced DNA cross-link damage and repair of specific DNA sequences in RT4 cells.
McKenna DJ; Gallus M; McKeown SR; Downes CS; McKelvey-Martin VJ
DNA Repair (Amst); 2003 Aug; 2(8):879-90. PubMed ID: 12893084
[TBL] [Abstract][Full Text] [Related]
26. Activity of quinone alkylating agents in quinone-resistant cells.
Begleiter A; Leith MK
Cancer Res; 1990 May; 50(10):2872-6. PubMed ID: 1692249
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and evaluation of the antitumor activity of 4,5-diamino-substituted 1,2-benzoquinones.
Huang ZD; Chen YN; Menon K; Teicher BA
J Med Chem; 1993 Jun; 36(13):1797-801. PubMed ID: 8515418
[TBL] [Abstract][Full Text] [Related]
28. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells.
Siegel D; Gibson NW; Preusch PC; Ross D
Cancer Res; 1990 Nov; 50(22):7293-300. PubMed ID: 2121335
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the structural and cytotoxic activity of novel 2,5-bis(carboethoxyamino)-3,6-diaziridinyl-1,4-benzoquinone analogues.
Dzielendziak A; Butler J; Hoey BM; Lea JS; Ward TH
Cancer Res; 1990 Apr; 50(7):2003-8. PubMed ID: 2156610
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZG, NSC 224070) during a phase I clinical trial.
Betteridge RF; Bosanquet AG; Gilby ED
Eur J Cancer; 1990 Feb; 26(2):107-12. PubMed ID: 2138904
[TBL] [Abstract][Full Text] [Related]
31. Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).
Savaraj N; Lu K; Feun LG; Leavens ME; Stewart D; Burgess MA; Benjamin RS; Loo TL
J Neurooncol; 1983; 1(1):15-9. PubMed ID: 6678302
[TBL] [Abstract][Full Text] [Related]
32. Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986).
Egorin MJ; Fox BM; Spiegel JF; Gutierrez PL; Friedman RD; Bachur NR
Cancer Res; 1985 Mar; 45(3):992-9. PubMed ID: 3971389
[TBL] [Abstract][Full Text] [Related]
33. Cross-linking and sequence specific alkylation of DNA by aziridinyl quinones. 2. Structure requirements for sequence selectivity.
Hargreaves RH; Mayalarp SP; Butler J; McAdam SR; O'Hare CC; Hartley JA
J Med Chem; 1997 Jan; 40(3):357-61. PubMed ID: 9022802
[TBL] [Abstract][Full Text] [Related]
34. DNA adducts of the antitumor agent diaziquone.
Gupta RC; Garg A; Earley K; Agarwal SC; Lambert GR; Nesnow S
Cancer Res; 1991 Oct; 51(19):5198-204. PubMed ID: 1913643
[TBL] [Abstract][Full Text] [Related]
35. Ability of a new antitumor agent, AZQ, to penetrate into cerebrospinal fluid.
Gormley PE; Wood JH; Poplack DG
Pharmacology; 1981; 22(3):196-8. PubMed ID: 7208602
[TBL] [Abstract][Full Text] [Related]
36. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
37. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Czechowska A; Poplawski T; Drzewoski J; Blasiak J
Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
[TBL] [Abstract][Full Text] [Related]
38. Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.
Curt GA; Kelley JA; Kufta CV; Smith BH; Kornblith PL; Young RC; Collins JM
Cancer Res; 1983 Dec; 43(12 Pt 1):6102-5. PubMed ID: 6640549
[TBL] [Abstract][Full Text] [Related]
39. Assessment of DNA interstrand crosslinks using the modified alkaline comet assay.
Wu JH; Jones NJ
Methods Mol Biol; 2012; 817():165-81. PubMed ID: 22147573
[TBL] [Abstract][Full Text] [Related]
40. Detection of DNA-crosslinking agents with the alkaline comet assay.
Pfuhler S; Wolf HU
Environ Mol Mutagen; 1996; 27(3):196-201. PubMed ID: 8625955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
